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Abstract
PURPOSE: To evaluate the variability and repeatability of repeated magnetic resonance imaging (MRI) measurements
in normal breast tissues between and within subjects. METHODS: Eighteen normal premenopausal subjects under-
went two contrast-enhanced MRI scans within 72 hours or during the same menstrual phase in two consecutive
months. A subset of nine women also completed diffusion-weighted imaging (DWI). Fibroglandular tissue (FGT)
density and FGT enhancement were measured on the contrast-enhanced MRI. Apparent diffusion coefficient
(ADC) values were computed from DWI. Between- and within-subject coefficients of variation (bCV and wCV,
respectively) were assessed. Repeatability of all measurements was assessed by the coefficient of repeatability
(CR) and Bland-Altman plots. RESULTS: The bCV of FGT density and FGT enhancement at visit 1 and visit 2 ranged
from 47% to 63%. The wCV was 13% for FGT density, 22% for FGT enhancement, and 11% for ADC. The CRs of
FGT density and FGT enhancement were 0.15 and 0.19, respectively, and for ADC, it was 6.1×10−4 mm2/s.
CONCLUSIONS: We present an estimate of the variability and repeatability of MR measurements in normal
breasts. These estimates provide the basis for understanding the normal variation of healthy breast tissue in MRI
and establishing thresholds for agreement between measurements.
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Introduction
High mammographic density is well established as an independent
risk factor for breast cancer [1]. However, challenges associated with
mammography such as inconsistency in instrumentation calibration,
variability in the extent of breast compression, and the limitations of
two-dimensional (2D) X-ray image projection are potential sources
of error in determining true breast density [2]. Hence, 3D quantita-
tive image-based methods have been investigated as alternatives to
mammographic density for prediction of breast cancer risk [3,4].
Magnetic resonance imaging (MRI) provides unprecedented sen-
sitivity and resolution in evaluating breast anatomy in 3D and has
been used to diagnostically evaluate and screen for breast cancer
[5,6]. Breast fibroglandular tissue (FGT) can be distinguished from
fatty tissue using 3D T1-weighted MRI with fat suppression, allowing
a 3D assessment of breast density. The level of enhancement in FGT
(also termed background parenchymal enhancement) by contrast-
enhanced MRI has also been shown to be a strong independent
predictor of breast cancer odds [7].
FGT enhancement can be characterized quantitatively by the per-
cent enhancement after an injection of contrast agent. More recently,
MR-based FGT density measurement has also been obtained using
a semiautomatic iterative segmentation technique based on a fuzzy
C-means (FCM) clustering algorithm. These quantitative measures of
breast tissue have been found to correlate well with mammographic
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density [8]. In addition to contrast-enhanced MRI, diffusion-weighted
imaging (DWI) has been investigated for characterization of normal
FGT [9]. DWI provides complementary quantitative measures, such
as the apparent diffusion coefficient (ADC), that reflect tissue cellularity
and vascularity [10].
Despite the benefit of its use as a potential breast cancer risk factor,
FGT characterization by MRI lacks specificity to differentiate malig-
nant from benign and normal tissues [11]. In particular, the contrast
enhancement profile of ductal carcinoma in situ (DCIS) may show
persistent enhancement similar to normal background parenchymal
enhancement. Without biopsy confirmation and experienced radio-
logic staff, DCIS may remain undetected [12]. Moreover, certain
patient characteristics such as hormonal changes may contribute to
FGT measurement variations that also lead to misdiagnoses [13,14].
These limitations underscore the need for an understanding of the
expected variability of background enhancement in normal FGT.
While some studies have attempted to estimate error in quantitative
parameters from MRI [15–18], there is no investigation on the vari-
ability and repeatability in FGT measurements by contrast-enhanced
MRI and DW-MRI. The purpose of this study was to characterize
normal FGT using MR background enhancement and density param-
eters in repeated scans to evaluate the variability and repeatability of
these measurements between and within normal subjects. In a subset
of this study, DWI was also acquired in an attempt to provide com-
plementary characterization of normal breast tissue. To control for
effects of hormonal fluctuation, measurements were taken during the
early follicular phase of the menstrual cycle when hormonal fluctuation
is minimal.
Materials and Methods
Study Population
Nineteen healthy female volunteers were enrolled in this Health
Insurance Portability and Accountability Act (HIPPA)-compliant
study protocol that was reviewed by the Institutional Review Board
and approved by the Committee of Human Research under the
institution’s Human Research Protection Program. All volunteers
provided written informed consent to participate in this study. Subjects
were initially scheduled for two contrast-enhanced MRI scans within
a 72-hour period. To control for image fluctuations arising from
elevated estrogen and progesterone levels during the luteal phase of
the menstrual cycle, every attempt was made to schedule both scans
during the follicular phase of the menstrual cycle. Subjects who were
unable to complete both scans within 72 hours (n = 6) were scheduled
to complete the second scan during the same phase of their next
menstrual cycle. Other subject characteristics such as age, day of
menstrual cycle, time between both scans, cycle length, and use of con-
traceptives were recorded. DWI was offered to all subjects and nine
subjects participated in the DWI scans before contrast-enhanced MRI.
Contrast-Enhanced MRI Acquisition
MRI was performed on a 1.5-T scanner (Signa; GE Healthcare,
Milwaukee, WI) using a dedicated bilateral eight-channel array breast
coil [Hologic (formerly Sentinelle Medical), Toronto, Ontario]. A
fat-suppressed T1-weighted 3D fast gradient-recalled echo sequence
was used [repetition time/echo time (RT/TE), 8.8/4.3; flip angle, 10°;
field of view (FOV) = 28-38 cm; imaging matrix = 512 × 320]. Bilateral
imaging of the breasts was performed in the axial orientation with
156 slices of 2-mm thickness in a scan time of 3minutes and 42 seconds,
with the low-order phase encoding data acquired around the
center of the scan. Gadopentetate dimeglumine (Magnevist; Bayer
HealthCare, Berlin, Germany) was used as a contrast agent and
was injected at a dose of 0.1 mmol/kg of body weight (1.2 ml/s)
followed by a 10-ml saline flush. Three time points were acquired
during each contrast-enhanced MRI examination: a baseline scan
before contrast agent injection (t0), followed by two time points
measured in the early (t1) and late phases (t2) after contrast injection,
yielding temporal post-contrast sampling times of 1.83 minutes and
5.67 minutes, respectively. Only the baseline and early time points
were used in this study.
DWI Acquisition
DWI data were acquired bilaterally in the axial orientation using a
fat-suppressed diffusion-weighted echo planar imaging sequence (TR =
6 seconds, TE = 109 milliseconds, b values = 0 and 600 s/mm2,
FOV = 40 cm, slice thickness = 3 mm, between slice gap = 0, imaging
matrix = 128 × 128, number of averages = 6, acquisition time = 4 min-
utes and 24 seconds). Diffusion gradients were applied in six directions.
Contrast-Enhanced MR Image Analysis
Although images were acquired bilaterally, for the purpose of this
study, all analyses were performed on the right breast. To isolate
FGT from fat in the breast, a two-step process was applied: 1) delinea-
tion of the total breast volume and 2) application of an unsupervised
FCM algorithm for FGT segmentation [8,19,20].
Total breast volume delineation. A previously described graphical
user interface was used to interactively delineate the contours of the
breast on individual image slices [8]. As shown in Figure 1A, delinea-
tion was accomplished by placing Bézier splines [8] along the contours
of the breast on individual slices. An algorithm based on the Laplacian-
of-a-Gaussian filter [21] automatically attached the Bézier splines to the
closest edge of the breast. Delineated regions on each of the 156 slices
of the pre-contrast T1-weighted 3D series comprised the total breast
volume. Given that the morphology of the breast does not change
significantly between contiguous slices, Bézier splines were drawn on
every four to six slices to reduce user interaction and computational
time [21]. Intermediate slices were linearly interpolated, visually in-
spected, and adjusted whenever Bézier splines were misaligned with
the contours of the breast.
FGT segmentation. The total breast volume was segmented into
FGT and fat by a semiautomated iterative classification [8]. Before
segmentation, image analysts defined the number of clusters to extract
from the breast volume. Nondiseased, noncontrast T1-weighted MR
images typically exhibit two broad categories of signal intensity that
correspond to FGT and fat. FGT presents as hyperintense relative to
suppressed fat. However, abnormalities such as cysts, benign lesions,
nonuniform signal intensity in FGT, and artifacts give rise to additional
categories. Hence, a total of five clusters was empirically determined to
account for all signal intensity categories within the total breast volume.
The algorithm assigned a membership (ratio of FGT) between “0”
and “1” to each voxel, where “1” indicated a voxel that was primarily
FGT and “0” indicated a voxel that was primarily fat. Such fuzzy
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classification has the advantage of minimizing artificial inflation or
deflation of FGT quantification within voxels that demonstrate partial
volume effects (i.e., possess contributions from multiple categories of
signal intensity). Moreover, fuzzy classification ensures that an accurate
percentage of FGT in each voxel is counted toward the FGT volume.
As shown in Figure 1B, five clusters were segmented from the total
breast volume. Trained image analysts decided which of the five clusters
comprised FGT based on visual inspection. Selected clusters were
combined into a mask (Figure 1C ), and the FGT volume was com-
puted as the sum of the memberships of all voxels within the mask.
FGT density estimation. After total breast volume delineation and
FGT segmentation, FGT density was calculated as the ratio of the
FGT volume to the total breast volume.
FGT enhancement quantification. FGT enhancement ((S1 − S0)/
S0) was computed on a voxel-by-voxel basis from contrast-enhanced
MRI as the relative change in signal intensity from the pre-contrast
(S0) to the early post-contrast (S1) time point. Voxels with intensity
decreased between the pre-contrast and post-contrast images were
excluded from the FGT enhancement analysis. Figure 2, A to C , dis-
plays a typical FGT enhancement map obtained by contrast-enhanced
MRI with 1) a representative pre-contrast image, 2) a corresponding
Figure 1. Representative contrast-enhanced MR image and FGT
delineation. (A) Pre-contrast enhanced image with superimposed
Bézier splines. Bézier splines were used to outline the contours of
the breast on pre-contrast enhanced images. These outlines over
all 156 slices constituted the total breast volume. (B) Intermediate
output of an FCM algorithm showing clusters of breast tissue
segmented from the total breast volume based on signal intensity:
Each of the five distinct shades represents a tissue cluster group.
Cluster groups were visually inspected to determine which cluster
groups were primarily FGT. (C) Final output of the FCM algorithm.
FGT cluster groups were combined into a mask with each voxel
in the mask possessing a membership from 0 to 1 representing
its FGT membership. The sum of these memberships comprised
the total FGT volume.
Figure 2. Representative contrast-enhanced MR image and FGT
enhancement illustration. (A) Pre-contrast enhanced image. (B) Early
contrast-enhanced image. (C) Illustration of all enhancing voxels
within the FGT volume superimposed onto the pre-contrast image.
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contrast-enhanced image, and 3) an illustration of all enhancing voxels
within the FGT volume superimposed onto the pre-contrast enhanced
image, respectively.
DWI Analysis
A mean FGT ADC was derived for each DWI scan. It was neces-
sary to separately delineate FGT on the diffusion weighted images
rather than applying the FGT volume derived from the contrast-
enhanced MR images onto the DWI images because of 1) a 2.5-fold
difference in slice thickness, 2) a 3-fold difference in voxel size between
the contrast-enhanced MRI and DWI images, and 3) distortions in the
DWI images. FGT delineation for DWI was accomplished by drawing
free-form regions of interest (ROIs) on the T2-weighted (b = 0 s/mm2)
images of the DWI acquisition. Figure 3A displays a representative
FGT ROI on a T2-weighted (b = 0 s/mm2) image. The mono-
exponential ADC was computed on a voxel-by-voxel basis using the
following equation:
ADC = −lnðS600=S0Þ=Δb ðmm2=sÞ; ð1Þ
where S0 and S600 are the signal intensities at b = 0 s/mm
2 and b = 600
s/mm2, respectively, and Δb = 600 s/mm2. The mean ADC of all voxels
within the FGT ROI was used for statistical analysis. Figure 3B displays
a representative ADC map.
Statistical Analysis
The variability of measurements (FGT density, FGT enhancement
and ADC) was assessed by the coefficient of variation (CV). The
between-subject CV (bCV) for a specific visit was defined as the ratio
of the standard deviation (SD) to the mean of measurements across
subjects at the same visit and expressed as a percentage (Equation 2):
bCV = 100 ×
SD
mean
: ð2Þ
The within-subject CV (wCV), also expressed in percentage terms, was
generated by the ratio of the within-subject SD (wSD) to the overall
mean of measurements from visit 1 and visit 2 (Equation 3), for
measurements Yv1 and Yv2 at visit 1 and visit 2, respectively:
wSD =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑ðYv1  Yv2Þ2
2n
s
; overall mean =
∑ðYv1 + Yv2Þ
2n
;
where the sums are over the n subjects in the study so that
wCV = 100 ×
wSD
overall mean
: ð3Þ
Repeatability of measurements refers to the strength of agreement
between repeated measurements obtained under similar conditions
[22]. Scatterplots of measurements at visit 2 versus visit 1 were evalu-
ated. Spearman rank correlation was used to assess the agreement
between visits, and results were reported with the Spearman rank
correlation coefficient (ρ) and 95% confidence intervals (CIs). Resid-
ual variance from the identity line (i.e., visit 2 = visit 1) was calcu-
lated on the basis of the sum of square of deviations and degree of
freedom (n − 2). Bland-Altman plots of the difference versus mean
of measurements from visit 1 to visit 2 were used to assess the re-
peatability of measurements and its relationship to the magnitude
of measurements [23]. Differences in measurements that fell within
the limits of agreement (LOA = mean difference ± 1.96 × SD of the
difference in measurements between visits 1 and 2 (SDdiff)) were
considered clinically unimportant [24]. The coefficient of repeat-
ability (CR = 1:96 ×
ﬃﬃﬃ
2
p
SDdiff ) was used to assess the reliability of
measurements. Kendall Tau test was used to assess the potential
correlation between the difference and the mean of measurements
between visits.
The impact of contraceptives, the nature of the subject’s menstrual
cycle (regular versus irregular), and the timing of repeated scans on
the repeatability of measurements was investigated using a linear
mixed-effects model fitted by restricted maximum likelihood [25].
Separate models were fit for each parameter (FGT density, FGT
enhancement, and ADC) as a fixed effect, along with subject-specific
random intercept and slope effects. All statistical analyses were per-
formed using R statistical analysis software package (R Development
Core Team (2013). R: a language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna, Austria.
ISBN 3-900051-07-0, URL: http://www.R-project.org/).
Figure 3. Representative image of DWI and FGT delineation.
(A) T2-weighted image with a superimposed FGT ROI. Due to dis-
tortion present in DWI as well as mismatch in slice thickness and
voxel size between both acquisitions, it was not possible to apply
FGT mask generated from contrast-enhanced MRI to DWI. Hence,
FGT ROIs were separately generated for DWI by drawing free-form
ROIs on non–diffusion-weighted images. (B) ADC map generated
from diffusion-weighted images. The mean ADC of all voxels within
the FGT ROI was used for statistical analysis.
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Results
Subject Characteristics
Detailed subject characteristics can be found in Table 1. Subjects’
ages ranged from 22 to 45 (median age, 28). All subjects were pre-
menopausal. One subject was excluded from the analysis because of
poor image quality from contrast-enhanced MRI. Fifteen subjects re-
ported regular menstrual cycles with cycle length ranging from 25 to 35
days, while three subjects reported irregular cycles. The day of menstru-
al cycle at the first visit ranged from 2 to 13 (median day, 9). Six of 18
subjects reported using oral contraceptives. All 18 subjects underwent
contrast-enhanced MRI scans at visit 1 and visit 2, with 12 subjects
completing both scans within 72 hours. A subset of nine subjects also
underwent DWI scans before contrast-enhanced MRI at both visits.
Between-Subject Variation
There was a considerable spread in measurements between all
subjects for all parameters measured. The spread of FGT density
among this cohort ranged from 0.031 to 0.73 with bCV of 61% at visit
1 and 63% at visit 2. The spread of FGT enhancement values was also
high, ranging from 0.080 to 0.45 with bCV of 47% and 54% at visits 1
and 2, respectively. The correlation between FGT density and FGT
enhancement was not statistically significant at either visit, but the
CIs are so wide that it is not possible to rule out clinically important
effects (visit 1: Spearman rank correlation, ρ = −0.17; 95% CI = −0.62,
0.36; P = .5; visit 2: Spearman rank correlation, ρ = −0.42; 95% CI =
−0.78, 0.07; P = .08). In the subset of nine subjects who underwent
DWI, the spread of ADC ranged from 1.7 × 10−3 to 2.8 × 10−3 mm2/s
at visit 1 and 1.4 × 10−3 to 2.8 × 10−3 mm2/s at visit 2. The bCV was
18% and 20% at visits 1 and 2, respectively.
Within-Subject Variation
In general, FGT density exhibited greater agreement between re-
peated measurements than FGT enhancement, with an interquartile
range of difference of 0.079 and wCV of 13%. The interquartile range
of difference between repeated FGT enhancement measurements was
0.12 with a higher wCV of 22%. For ADC, the interquartile range of
difference was 0.14 × 10−3 mm2/s and the wCV was 11%.
Figure 4. Relationships of repeated measurements from visits 1
and 2 are shown in the scatterplots with an equality line for (A)
FGT density, (B) FGT enhancement, and (C) ADC.
Table 1. Subject Characteristics.
ID Age Day of Menstrual
Cycle at Visit 1
Days between Scans Cycle Length Contraceptive Completed DWI
1 25.0 3 2 28 + +
2 24.9 7 2 28 + −
3 26.5 7 57 28 + +
4 38.8 7 2 28 − −
5 28.4 12 2 28 + +
6 27.3 10 69 35 − −
7 40.6 8 9 Irregular − −
8 22.4 11 2 Irregular − +
9 21.8 10 2 30 − +
10 42.8 13 2 31 − −
11 31.6 9 2 30 − −
12 21.9 5 9 20 − −
13 45.1 12 2 30 − −
14 29.8 2 2 27 + −
15 24.8 6 37 25 + +
16 26.9 10 2 26 − +
17 37.6 13 27 Irregular − +
18 42.5 8 2 28 − +
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Repeatability Analysis
Repeatability of all measurements was first evaluated in a scatterplot
of measurements at visit 2 versus visit 1. As shown in Figure 4, there
was a strong agreement of FGT density between measurements with a
residual variance from the identity line (i.e., visit 2 = visit 1) of 0.0039
and a Spearman rank correlation coefficient of 0.95 (95% CI = 0.80,
1.00; P < .0001). FGT enhancement, however, showed a weaker
agreement with a residual variance of 0.0048 and a Spearman rank cor-
relation coefficient of 0.75 (95%CI = 0.40, 0.92; P = .0003). Repeated
measurements of ADC also showed weak agreement with a residual
variance of 5.8 × 10−8 mm4/s2 from the identity line and a Spearman
rank correlation coefficient of 0.57 (95% CI = −0.22, 1.00; P = .12).
Bland-Altman plots were also used to capture the repeatability of
measurements (Figure 5). Differences between measurements at visit 1
and visit 2 were plotted against the average of measurements at both
visits. The mean difference between the two measurements for FGT
density was 0.024 with lower/upper LOA (95% CI) of −0.085
(−0.12, −0.046)/0.13 (0.094, 0.17) and a CR of 0.15. FGT enhance-
ment showed a weaker correlation between the measurements at both
visits, but the Bland-Altman plot showed a mean difference of 0.0016
with the lower/upper LOA (95% CI) of −0.13 (−0.18, −0.084)/0.13
(0.087, 0.18) and a CR of 0.19. The mean difference between the
repeated ADCmeasurements was −3.8 × 10−5 mm2/s with lower/upper
LOA (95% CI) of −4.7 × 10−5 mm2/s (−7.1 × 10−4 mm2/s, −2.3 ×
10−4 mm2/s)/4 × 10−4 mm2/s (1.6 × 10−4 mm2/s, 6.3 × 10−4 mm2/s)
and a CR of 6.1 × 10−4 mm2/s. An outlier was observed in ADC
measurements (Figure 5C ); upon excluding it, the mean difference
between the repeated ADC measurements was 1.9 × 10−5 mm2/s with
lower/upper LOA (95%CI) of −2.8 × 10−4 mm2/s (−4.6 × 10−4 mm2/s,
−1 × 10−4mm2/s)/3.2 × 10−4mm2/s (1.4 × 10−4mm2/s, 5 × 10−4mm2/s)
and a CR of 4.2 × 10−4 mm2/s. Using the Kendall Tau test, the Bland-
Altman plots did not reveal any clear relationships between the difference
and the mean of repeated measurements for any of the parameters
measured, suggesting that the observed differences were independent of
the magnitude of the measurements.
Linear Mixed Effect Modeling
The effects of the covariates assessed, i.e., contraceptive use, regular
menstrual cycle, and repeat scan timing, on the parameters measured
are summarized in Table 3. None showed a significant effect in any of
the measured parameters.
The (nonstatistically significant) estimated effect of the use of
contraceptives was an increase in FGT density (0.12; 95% CI =
−0.079, 0.33; P = .21), a decrease in FGT enhancement (−0.035; 95%
CI = −0.14, 0.072; P = .5), and a decrease in ADC (−1 × 10−4 mm2/s;
95% CI = −8.2 × 10−4 mm2/s, 6.2 × 10−4 mm2/s; P = .75). Meanwhile,
the estimated effect of a regular menstrual cycle was to (nonstatistically
significant) increase all parameters: FGT density (0.18; 95% CI =
−0.89, 0.44; P = .18), FGT enhancement (0.036; 95% CI = −0.104,
0.18; P = .59), ADC (1.2 × 10−4 mm2/s; 95% CI = −4.7 × 10−4 mm2/
s, 7.1 × 10−4 mm2/s; P = .64). The estimated effect of completing both
scans within the same menstrual cycle was also a (nonstatistically sig-
nificant) increase in all parameters: FGT density (0.041; 95% CI =
−0.17, 0.26; P = .7), FGT enhancement (0.039; 95% CI = −0.071,
0.15; P = .46), ADC (2.2 × 10−4 mm2/s; 95% CI = −3.9 × 10−4, 8.2 ×
10−4; P = .42).
Discussion
Since the introduction of breast contrast-enhanced MRI in mid-1980s,
MRI has played a key clinical role in the staging and characterization
of primary and recurrent breast cancer [26]. MRI has demonstrated
high sensitivity in detecting breast cancer, leading to the use of
contrast-enhanced MRI for screening asymptomatic women who are
at high risk for breast cancer [27]. The characteristic contrast uptake/
washout kinetics in breast cancer reflects the morphologic and func-
tional properties that discern diseased from normal breast tissues. How-
ever, the specificity of contrast-enhanced MRI is challenged by the
strong FGT enhancement common in premenopausal women and
is influenced by estrogen levels [7,11,28]. In these cases, strong FGT
enhancement often obscures nonmass nodular malignant tissues such
as those found in preinvasive DCIS [29]. In addition, misinterpretation
of benign enhancement in fibroadenomas, atypical hyperplasia, and
lobular carcinoma in situ may result in false positive results [26].
With the development of increasingly sophisticated techniques to
improve quantitative evaluation of the breast, it is more essential than
ever to gain a better understanding of normal tissue MRI characteristics
[29]. Moreover, the development of quantitative imaging markers
to assess breast cancer risk or response to neoadjuvant chemotherapy
requires validation of the repeatability of imaging techniques. Surpris-
ingly, despite the routine use of MRI for breast cancer diagnosis, little
data exist on the repeatability of breast MRI in general, and data
regarding variability and repeatability of quantitative measurements
from breast contrast-enhanced MRI are even less available.
In this work, we conducted a repeated MRI study of 18 healthy
female subjects to assess contrast-enhanced and diffusion imaging para-
meters in normal breasts. To limit bias from physiological changes that
affect estrogen levels [30,31], all subjects were premenopausal, were in
the follicular phase of their menstrual cycle, and were imaged either
twice within a 72-hour window or at the same menstrual phase in
two consecutive months. A separate analysis without the six subjects
imaged in consecutive months showed that this exclusion did not
substantially alter the pattern of results; hence, the data acquired were
suitable for the subsequent variability and repeatability analysis.
Among the cohort of 18 subjects we examined, there was a wide
spread in FGT density and FGT enhancement, with between-subject
variation (bCV) ranging between 61% and 63% and 47% and 54%,
Table 2. Summary of Results of Variability and Repeatability.
Measurements Bias* bCV Visit 1 bCV Visit 2 wCV CR Lower LOA (95% CI) Upper LOA (95% CI)
FGT density 0.024 61% 63% 13% 0.15 −0.085 (−0.12, −0.046) 0.13 (0.094, 0.17)
FGT enhancement 0.0016 47% 54% 22% 0.19 −0.13 (−0.18, −0.084) 0.13 (0.087, 0.18)
ADC (mm2/s) −3.8 × 10−5 18% 20% 11% 6.1 × 10−4 −4.7 × 10−4 (−7.1 × 10−4, −2.3 × 10−4) 4 × 10−4 (1.6 × 10−4, 6.3 × 10−4)
*Bias = mean difference between visits.
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respectively, suggesting that the FGT density and FGT enhancement
values are highly subject dependent. While FGT density is the amount
of FGT in the total breast volume, FGT enhancement is the contrast
enhancement measured in the background parenchymal region. Al-
though both FGT density and FGT enhancement may have potential
as risk factors for breast cancer, they measure different characteristics
of FGT in the breast. The lack of meaningful correlation between
FGT density and FGT enhancement parallels similar observations that
MR FGT enhancement and mammographic density are not well cor-
related [32,33] and that these parameters are considered independent
risk factors for breast cancer [7].
In the subset of nine subjects that underwent the DWI study, the
spread of mean ADC was 1.4 × 10−3 mm2/s to 2.8 × 10−3 mm2/s with
bCV in the range of 18% and 20%. These results suggest that ADC
measurements might be less subject dependent than FGT density or
FGT enhancement measurements. The range of ADC values observed
in this study is consistent with ADC values previously reported in
healthy breast tissues [9,18,34]. While other studies have examined
the variability in the ADC stemming from hormonal fluctuations
during the menstrual cycle [34], no studies we encountered have
studied repeatability in the ADC with hormonal effects being treated
as a controlled parameter.
Between-visit measurement variations were assessed by wCV. FGT
density showed higher agreement compared to FGT enhancement,
with wCV of 13% versus 22%. The higher variability in FGT en-
hancement may be attributed to the subtle hormonal fluctuation that
has less influence in the FGT density measurement. Therefore, careful
study design to limit hormonal change in subjects would be prudent
when using FGT enhancement to assess normal breast. The wCV for
the ADC in nine subjects was 11%. Although it was lower than that
of both FGT density and FGT enhancement, further study with an
expanded population size is recommended to confirm this finding.
In the present study, contraceptive use, regular menstrual cycle,
and repeat scan timing did not have a meaningful impact on repeated
measurements. Although unlikely, variability of imaging quality
because of changes in scanner performance between repeat visits and
across patients cannot be ruled out. Future study design will benefit
from periodic calibration scans.
One factor that could impact repeatability of FGT density estimates
is subject positioning. Our estimation of FGT density assumes that the
total breast volume is uncompressed. While no gross compression was
evident for any patients, it is tenable, especially in larger patients, that
compression of the breast between repeat visits might skew estimates
of the total breast volume and, resultantly, the estimated FGT density.
Temperature and gradient nonlinearity are factors that may impact
the variability and repeatability of the ADC. In the current study, we
did not control for temperature. Hence, it is plausible that DWI mea-
surements between repeat visits and across patients may have been
acquired at a different temperature. Gradient nonlinearity is more
pronounced at distances offset from the isocenter of the magnet, espe-
cially in breast imaging. Repositioning of patients in repeated scans may
further affect the variability to the ADC values. Finally, it should also
be noted that DWI analysis was only performed on a subset of nine
subjects; hence, the presented ADC results are limited in scope and
should be interpreted accordingly.
In summary, we presented a preliminary estimate of expected
variability and repeatability of quantitative FGT density, FGT en-
hancement, and ADC measurements in the normal breast. We antici-
pate expanding this analysis with a larger population and other DWI
Figure 5. Bland-Altman plots of difference in measurements from
visit 1 to visit 2 versus average of measurements from both visits.
Upper and lower dotted lines represent the LOA; the center dotted
line is the mean difference. (A) FGT density measurement with a
mean difference at 0.024 and LOA (95% CI) of −0.085 (−0.12,
−0.046) and 0.13 (0.094, 0.17). (B) FGT enhancement measure-
ments with a mean difference at 0.0016 and LOA (95% CI) of
−0.13 (−0.18, −0.084) and 0.13 (0.087, 0.18). (C) ADC measure-
ments (× 10−3) with a mean difference of −0.038 mm2/s and LOA
(95%CI) of−0.47mm2/s (−0.71mm2/s,−0.23mm2/s) and0.4mm2/s
(0.16 mm2/s, 0.63 mm2/s).
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quantifiers. These estimates form the basis for normal variation of
FGT as measured by MRI and will guide the correct interpretation
of cancer diagnosis and assessment of tumor treatment response.
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